These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 39263686)

  • 1. Brolucizumab versus aflibercept for recalcitrant diabetic macular edema in Indian real-world scenario - The BRADIR study.
    Chakraborty D; Sharma A; Mondal S; Sheth J; Sinha TK; Boral S; Mukherjee A; Bhattacharya R; Maitra R
    Am J Ophthalmol Case Rep; 2024 Dec; 36():102152. PubMed ID: 39263686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Brolucizumab for Diabetic Macular Edema: The KINGFISHER Randomized Clinical Trial.
    Singh RP; Barakat MR; Ip MS; Wykoff CC; Eichenbaum DA; Joshi S; Warrow D; Sheth VS; Stefanickova J; Kim YS; He F; Cho GE; Wang Y; Emanuelli A
    JAMA Ophthalmol; 2023 Dec; 141(12):1152-1160. PubMed ID: 37971723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Experience with Brolucizumab Compared to Aflibercept in Treatment-Naïve and Therapy-Refractory Patients with Diabetic Macular Edema.
    Rübsam A; Hössl L; Rau S; Böker A; Zeitz O; Joussen AM
    J Clin Med; 2024 Mar; 13(6):. PubMed ID: 38542043
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of brolucizumab versus aflibercept in patients with neovascular age-related macular degeneration: a randomized trial in Indian patients.
    Mishra SK; Kumar P; Khullar S; Joshi A; Sati A; Kumar SV; Unni D; Kumar A
    Int J Retina Vitreous; 2022 Jul; 8(1):51. PubMed ID: 35902887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema.
    Brown DM; Emanuelli A; Bandello F; Barranco JJE; Figueira J; Souied E; Wolf S; Gupta V; Ngah NF; Liew G; Tuli R; Tadayoni R; Dhoot D; Wang L; Bouillaud E; Wang Y; Kovacic L; Guerard N; Garweg JG
    Am J Ophthalmol; 2022 Jun; 238():157-172. PubMed ID: 35038415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluid Control in Neovascular Age-Related Macular Degeneration with Brolucizumab: An Analysis of the HAWK and HARRIER Phase 3 Trials.
    Regillo C; Singh R; Hamilton R; Gedif K; Best C; Koh A; Holz FG
    Ophthalmologica; 2022; 245(5):403-412. PubMed ID: 35468601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy Outcomes of Brolucizumab Versus Aflibercept in Neovascular Age-Related Macular Degeneration Patients with Early Residual Fluid.
    Singh RP; Jhaveri C; Wykoff CC; Gale RP; Staurenghi G; Iida T; Koh A; B G; Gedif K; Singer M
    Ophthalmol Retina; 2022 May; 6(5):377-386. PubMed ID: 34968756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Off-label intravitreal brolucizumab for recalcitrant diabetic macular edema: A real-world case series.
    Chakraborty D; Sheth JU; Boral S; Sinha TK
    Am J Ophthalmol Case Rep; 2021 Dec; 24():101197. PubMed ID: 34504981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid.
    Khanani AM; Brown DM; Jaffe GJ; Wykoff CC; Adiguzel E; Wong R; Meng X; Heier JS;
    Ophthalmology; 2022 Sep; 129(9):974-985. PubMed ID: 35537533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
    Dugel PU; Singh RP; Koh A; Ogura Y; Weissgerber G; Gedif K; Jaffe GJ; Tadayoni R; Schmidt-Erfurth U; Holz FG
    Ophthalmology; 2021 Jan; 128(1):89-99. PubMed ID: 32574761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK.
    Ogura Y; Jaffe GJ; Cheung CMG; Kokame GT; Iida T; Takahashi K; Lee WK; Chang AA; Monés J; D'Souza D; Weissgerber G; Gedif K; Koh A
    Br J Ophthalmol; 2022 Jul; 106(7):994-999. PubMed ID: 34301613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
    Dugel PU; Koh A; Ogura Y; Jaffe GJ; Schmidt-Erfurth U; Brown DM; Gomes AV; Warburton J; Weichselberger A; Holz FG;
    Ophthalmology; 2020 Jan; 127(1):72-84. PubMed ID: 30986442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of brolucizumab in age-related macular degeneration: A systematic review of real-world studies.
    Baumal CR; Sørensen TL; Karcher H; Freitas RL; Becher A; Balez S; Clemens A; Singer M; Kodjikian L
    Acta Ophthalmol; 2023 Mar; 101(2):123-139. PubMed ID: 36117281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success.
    Laiginhas R; Silva MI; Rosas V; Penas S; Fernandes VA; Rocha-Sousa A; Carneiro Â; Falcão-Reis F; Falcão MS
    Graefes Arch Clin Exp Ophthalmol; 2018 Jan; 256(1):83-89. PubMed ID: 29082448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brolucizumab for the treatment of diabetic macular edema.
    Kuo BL; Singh RP
    Curr Opin Ophthalmol; 2022 May; 33(3):167-173. PubMed ID: 35266896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between intravitreal brolucizumab and aflibercept in the treatment-naive central involved diabetic macular edema: One-year real-life case series.
    Elhamaky TR
    Eur J Ophthalmol; 2024 May; 34(3):797-802. PubMed ID: 37817540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial.
    Dugel PU; Jaffe GJ; Sallstig P; Warburton J; Weichselberger A; Wieland M; Singerman L
    Ophthalmology; 2017 Sep; 124(9):1296-1304. PubMed ID: 28551167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
    Virgili G; Curran K; Lucenteforte E; Peto T; Parravano M
    Cochrane Database Syst Rev; 2023 Jun; 2023(6):CD007419. PubMed ID: 38275741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term Efficacy and Safety of Intravitreal Brolucizumab Injection for Treatment-Naive Exudate Age-related Macular Degeneration: A Multicenter Study.
    Kim J; Lee SJ; Park TK; Sun HJ; Kim HD; Cho IH; Han JW; Choi KS
    Korean J Ophthalmol; 2023 Oct; 37(5):365-372. PubMed ID: 37562440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal Brolucizumab and Aflibercept for Polypoidal Choroidal Vasculopathy.
    Cho HJ; Kang KH; Yoon W; Lee J; Kim CG; Kim JW
    J Ocul Pharmacol Ther; 2023 Nov; 39(9):653-660. PubMed ID: 37504966
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.